Aberdeen Group plc Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Aberdeen Group plc boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 218,624 shares of the biopharmaceutical company’s stock after buying an additional 3,239 shares during the period. Aberdeen Group plc owned approximately 0.17% of Alnylam Pharmaceuticals worth $70,364,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. grew its position in Alnylam Pharmaceuticals by 11.7% in the 2nd quarter. Blue Trust Inc. now owns 1,293 shares of the biopharmaceutical company’s stock valued at $422,000 after buying an additional 135 shares during the last quarter. Callan Family Office LLC lifted its holdings in Alnylam Pharmaceuticals by 187.9% in the second quarter. Callan Family Office LLC now owns 2,931 shares of the biopharmaceutical company’s stock valued at $956,000 after acquiring an additional 1,913 shares during the period. Vontobel Holding Ltd. lifted its holdings in Alnylam Pharmaceuticals by 72.5% in the second quarter. Vontobel Holding Ltd. now owns 2,917 shares of the biopharmaceutical company’s stock valued at $951,000 after acquiring an additional 1,226 shares during the period. Shell Asset Management Co. lifted its holdings in Alnylam Pharmaceuticals by 28.3% in the second quarter. Shell Asset Management Co. now owns 7,257 shares of the biopharmaceutical company’s stock valued at $2,366,000 after acquiring an additional 1,602 shares during the period. Finally, KLP Kapitalforvaltning AS lifted its holdings in Alnylam Pharmaceuticals by 12.4% in the second quarter. KLP Kapitalforvaltning AS now owns 49,100 shares of the biopharmaceutical company’s stock valued at $16,011,000 after acquiring an additional 5,400 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 0.6%

NASDAQ:ALNY opened at $459.66 on Friday. The company has a market capitalization of $60.25 billion, a PE ratio of -186.10 and a beta of 0.36. The stock has a fifty day simple moving average of $451.37 and a 200-day simple moving average of $345.60. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of recent analyst reports. Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a report on Friday, August 1st. HC Wainwright reissued a “buy” rating and issued a $570.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday. Citigroup raised their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Bank of America lifted their price target on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Finally, Raymond James Financial began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price target for the company. Twenty-four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $457.16.

Insider Activity

In related news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the sale, the executive vice president owned 25,231 shares in the company, valued at approximately $11,405,673.55. This trade represents a 8.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the sale, the executive vice president owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. This represents a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,144 shares of company stock worth $44,160,261 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.